期刊
BIOMED RESEARCH INTERNATIONAL
卷 2013, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2013/581631
关键词
-
资金
- National Natural Scientific Foundation of China [81270472, 81070310]
The pathogenesis and treatment of inflammatory bowel disease (IBD) have been recently advanced, while it is still challenged with high morbidity and poor prognosis. Infliximab, a monoclonal antibody of tumor necrosis factor (TNF), has emerged as an efficient treatment with many clinical benefits such as quick disease activity reduction and IBD patient life quality improvement. However, the biological effects of infliximab on IBD need to be elucidated.. is paper reviewed the clinical use and recently advanced biological action of infliximab on IBD. By forming the stable complex with the soluble or the membrane form of TNF in fluid environment or on cell surface of immune cell, fibroblast, endothelium, and epithelium, infliximab quenches TNF activity and performs the important biological actions which lead to amelioration and remission of immune responses.. e mechanisms of infliximab treatment for IBD were intensively discussed.. e recent advances on two topics including predictors and side effects of infliximab treatment were also reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据